P J Neumann

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi request reprint Are methods for estimating QALYs in cost-effectiveness analyses improving?
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 17:402-8. 1997
  2. ncbi request reprint Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 57:957-64. 2001
  3. ncbi request reprint Why don't Americans use cost-effectiveness analysis?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 10:308-12. 2004
  4. ncbi request reprint Growth and quality of the cost-utility literature, 1976-2001
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 8:3-9. 2005
  5. ncbi request reprint Economic messages in prescription drug advertisements in medical journals
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Care 40:840-5. 2002
  6. ncbi request reprint Do drug formulary policies reflect evidence of value?
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 12:30-6. 2006
  7. ncbi request reprint Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Pharmacoeconomics 23:537-41. 2005
  8. ncbi request reprint A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Decis Making 20:413-22. 2000
  9. ncbi request reprint Do HEDIS measures reflect cost-effective practices?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Prev Med 23:276-89. 2002
  10. ncbi request reprint Preference-based measures in economic evaluation in health care
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Annu Rev Public Health 21:587-611. 2000

Research Grants

Collaborators

Detail Information

Publications82

  1. ncbi request reprint Are methods for estimating QALYs in cost-effectiveness analyses improving?
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 17:402-8. 1997
    ..The objectives of this study were to examine variations in the methods used by researchers to estimate QALYs in published cost-effectiveness analyses, and to investigate whether the methods have improved over time...
  2. ncbi request reprint Measuring Alzheimer's disease progression with transition probabilities: estimates from CERAD
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 57:957-64. 2001
    ....
  3. ncbi request reprint Why don't Americans use cost-effectiveness analysis?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 10:308-12. 2004
    ..This paper examines the resistance to CEA in the United States and explores ways in which to advance the field...
  4. ncbi request reprint Growth and quality of the cost-utility literature, 1976-2001
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Value Health 8:3-9. 2005
    ..This study updates and expands our previous work, which examined CUAs through 1997...
  5. ncbi request reprint Economic messages in prescription drug advertisements in medical journals
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Care 40:840-5. 2002
    ..Our objectives were to examine how often prescription drug advertisements in leading medical journals contain economic messages, and to determine the types of promotional claims made and whether supporting evidence is provided...
  6. ncbi request reprint Do drug formulary policies reflect evidence of value?
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Am J Manag Care 12:30-6. 2006
    ..To investigate the extent to which preferred drug lists and tiered formularies reflect evidence of value, as measured in published cost-utility analyses (CUAs)...
  7. ncbi request reprint Health utilities in Alzheimer's disease and implications for cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Pharmacoeconomics 23:537-41. 2005
    ..The NICE assumption that they do not results in a difference in utilities between dependent and non-dependent AD individuals of only 0.06. This seems to be at the low end of what one would consider a reasonable estimate...
  8. ncbi request reprint A comparison of HUI2 and HUI3 utility scores in Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Decis Making 20:413-22. 2000
    ..The authors compared HUI2 and HUI3 scores of patients with Alzheimer's disease (AD) and caregivers, and contrasted results of a cost-effectiveness analysis of new drugs for AD using the two systems...
  9. ncbi request reprint Do HEDIS measures reflect cost-effective practices?
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Am J Prev Med 23:276-89. 2002
    ..Our study objectives were to examine the cost-effectiveness evidence for the clinical practices underlying HEDIS 2000 measures and to develop a list of practices not reflected in HEDIS that have evidence of cost effectiveness...
  10. ncbi request reprint Preference-based measures in economic evaluation in health care
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Annu Rev Public Health 21:587-611. 2000
    ..Widespread acceptance of the methodology likely awaits more consensus on measurement techniques, as well as educational efforts in the public health and medical communities on the usefulness of the approach...
  11. ncbi request reprint The quality of reporting in published cost-utility analyses, 1976-1997
    P J Neumann
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Ann Intern Med 132:964-72. 2000
    ..We examined quality of reporting by journal type and number of cost-utility analyses a journal has published...
  12. ncbi request reprint Health utilities in Alzheimer's disease: a cross-sectional study of patients and caregivers
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Med Care 37:27-32. 1999
    ....
  13. ncbi request reprint Cost-effectiveness of donepezil in the treatment of mild or moderate Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, MA 02115, USA
    Neurology 52:1138-45. 1999
    ..To demonstrate the use of cost-effectiveness analysis to assess the economic impact of donepezil in the treatment of mild or moderate AD...
  14. ncbi request reprint Medicare's national coverage decisions, 1999-2003: quality of evidence and review times
    Peter J Neumann
    Harvard School of Public Health in Boston, Massachusetts, USA
    Health Aff (Millwood) 24:243-54. 2005
    ..Decisions referred to the external Medicare Coverage Advisory Committee (MCAC) have averaged eight months longer than non-MCAC decisions...
  15. ncbi request reprint Methods of cost-effectiveness analysis in the assessment of new drugs for Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology, Harvard School of Public Health, Boston, MA 02115, USA
    Psychiatr Serv 48:1440-4. 1997
    ....
  16. ncbi request reprint Can we better prioritize resources for cost-utility research?
    Peter J Neumann
    Harvard School of Public Health, Boston, MA 02115, USA
    Med Decis Making 25:429-36. 2005
    ....
  17. ncbi request reprint Who gets chemotherapy for metastatic lung cancer?
    C C Earle
    Center for Outcomes and Policy Research, Department of Adult Oncology Dana Farber Cancer Institute, Boston, MA 02115, USA
    Chest 117:1239-46. 2000
    ..To determine the prevalence and factors associated with chemotherapy use in elderly patients presenting with advanced lung cancer...
  18. ncbi request reprint The association between caregiver burden and caregiver health-related quality of life in Alzheimer disease
    C M Bell
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Alzheimer Dis Assoc Disord 15:129-36. 2001
    ..The development of condition-specific preference-weighted instruments may provide the means to better estimate HRQOL in AD caregivers...
  19. ncbi request reprint Modeling for health care and other policy decisions: uses, roles, and validity
    M C Weinstein
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    Value Health 4:348-61. 2001
    ..Implications for the implementation of Section 114 of the Food and Drug Administration Modernization Act (FDAMA) are derived from this framework...
  20. ncbi request reprint An off-the-shelf help list: a comprehensive catalog of preference scores from published cost-utility analyses
    C M Bell
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Decis Making 21:288-94. 2001
    ..hsph.harvard.edu/organizations/hcra/cuadatabase/ intro.html) may provide a useful reference tool for producers and consumers of CUAs but also underscores the methodologic variation and inconsistencies present in the field...
  21. ncbi request reprint Systematic overview of cost-utility assessments in oncology
    C C Earle
    Center for Outcomes and Policy Research, Department of Adult Oncology, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 18:3302-17. 2000
    ..We critically reviewed the CUA literature and its role in informing clinical oncology practice, research priorities, and policy...
  22. pmc Measuring the value of public health systems: the disconnect between health economists and public health practitioners
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    Am J Public Health 98:2173-80. 2008
    ..g., social justice and reassurance value). Academic researchers evaluating the economics of public health investments should increase focus on the working needs of public health professionals...
  23. ncbi request reprint Cost-effectiveness of migraine prevention: the case of topiramate in the UK
    J S Brown
    Harvard Medical School Harvard Pilgrim Health Care, Department of Ambulatory Care and Prevention, Boston, MA, USA
    Cephalalgia 26:1473-82. 2006
    ..This analysis suggests that topiramate is a cost-effective treatment for migraine prevention compared with no preventive treatment...
  24. ncbi request reprint Do oncologists believe new cancer drugs offer good value?
    Eric Nadler
    Dana Faber Cancer Institute Harvard Medical School, Boston, MA, USA
    Oncologist 11:90-5. 2006
    ..Oncologists play a pivotal role in treatment decisions, yet it is unclear whether they perceive high-cost new treatments to offer good value or how therapeutic costs factor into their treatment recommendations...
  25. ncbi request reprint Costing and perspective in published cost-effectiveness analysis
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Med Care 47:S28-32. 2009
    ..Questions linger about what cost components to include under a "societal" perspective, as well as how to value resources...
  26. ncbi request reprint Evidence-based and value-based formulary guidelines
    Peter J Neumann
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts, USA
    Health Aff (Millwood) 23:124-34. 2004
    ..This paper describes the guidelines, reviews progress to date, and analyzes several critical issues for the future...
  27. doi request reprint A bibliometric review of cost-effectiveness analyses in the economic and medical literature: 1976-2006
    Dan Greenberg
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Med Decis Making 30:320-7. 2010
    ..Despite the proliferation of CEA research, there has been no detailed study focusing on the bibliometric properties of this literature...
  28. ncbi request reprint Quality of clinical and economic evidence in dossier formulary submissions
    Fernando Colmenero
    Harvard School of Public Health, Boston, MA, USA
    Am J Manag Care 13:401-7. 2007
    ..To investigate the quality and completeness of clinical and economic data in dossiers submitted by drug companies to a health plan using Academy of Managed Care Pharmacy guidelines (the Format) for formulary submissions...
  29. ncbi request reprint Effectiveness of chemotherapy for advanced lung cancer in the elderly: instrumental variable and propensity analysis
    C C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Institute, Boston, MA 02115, USA
    J Clin Oncol 19:1064-70. 2001
    ..To compare the effectiveness of chemotherapy given to elderly patients in routine practice for stage IV non-small-cell lung cancer (NSCLC) with the efficacy observed in randomized trials...
  30. ncbi request reprint Impact of referral patterns on the use of chemotherapy for lung cancer
    Craig C Earle
    Center for Outcomes and Policy Research, Dana Farber Cancer Center, Boston, MA 02115, USA
    J Clin Oncol 20:1786-92. 2002
    ..To determine the extent to which unexplained variation in the use of chemotherapy for advanced lung cancer is due to access to oncologists' services as opposed to treatment decisions made after seeing an oncologist...
  31. pmc Cost-effective diagnostic cardiovascular imaging: when does it provide good value for the money?
    Hansel J Otero
    Department of Radiology, Tufts Medical Center and Tufts University School of Medicine, Boston, MA 02111, USA
    Int J Cardiovasc Imaging 26:605-12. 2010
    ..The studies available have, in general, favorable cost-effectiveness profiles with major determinants relating to being compared against observation, medical or no intervention instead of other imaging tests...
  32. ncbi request reprint Cost-utility analyses in orthopaedic surgery
    Carmen A Brauer
    Harvard Center for Risk Analysis, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    J Bone Joint Surg Am 87:1253-9. 2005
    ..We critically reviewed the literature on orthopaedic cost-utility analysis to determine which subspecialty areas are represented, the cost-utility ratios that have been utilized, and the quality of the present literature...
  33. ncbi request reprint The arrival of economic evidence in managed care formulary decisions: the unsolicited request process
    Peter J Neumann
    Department of Policy and Decision Sciences, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Med Care 43:27-32. 2005
    ..This article describes the unsolicited request process and its potential impact on the use of economic evidence in formulary decisions...
  34. ncbi request reprint Long-term persistence in use of statin therapy in elderly patients
    Joshua S Benner
    Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women s Hospital and Harvard Medical School, 221 Longwood Ave, Suite 341, Boston, MA 02115, USA
    JAMA 288:455-61. 2002
    ....
  35. ncbi request reprint Trends in the measurement of health utilities in published cost-utility analyses
    Carmen A Brauer
    Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Value Health 9:213-8. 2006
    ..tufts-nemc.org/cearegistry; previously at http://www.hsph.harvard.edu/cearegistry), and documents recent changes in methods used for utility weight elicitation...
  36. ncbi request reprint Medicare and cost-effectiveness analysis
    Peter J Neumann
    Department of Health Policy and Management and the Center for Risk Analysis, Harvard School of Public Health, Boston, USA
    N Engl J Med 353:1516-22. 2005
  37. doi request reprint The adoption of cost-effectiveness acceptability curves in cost-utility analyses
    Lisa M Meckley
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts 02111, USA
    Med Decis Making 30:314-9. 2010
    ..g., life-years or quality-adjusted life-years gained)...
  38. ncbi request reprint Direct-to-consumer advertising and shared liability for pharmaceutical manufacturers
    Michelle M Mello
    Department of Health Policy and Management, Harvard School of Public Health, 677 Huntington Ave, Boston, Mass 02115, USA
    JAMA 289:477-81. 2003
  39. pmc Delays in publication of cost utility analyses conducted alongside clinical trials: registry analysis
    Dan Greenberg
    Harvard Center for Risk Analysis, Department of Health Policy and Management, Harvard School of Public Health, 718 Huntington Avenue, Boston, MA 02115, USA
    BMJ 328:1536-7. 2004
  40. ncbi request reprint When does quality-adjusting life-years matter in cost-effectiveness analysis?
    Richard H Chapman
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Health Econ 13:429-36. 2004
    ....
  41. ncbi request reprint The impact of risk information on patients' willingness to pay for autologous blood donation
    S J Lee
    Division of Hematology Oncology, Brigham and Women s Hospital, Boston, MA, USA
    Med Care 36:1162-73. 1998
    ....
  42. ncbi request reprint Emerging lessons from the drug effectiveness review project
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, Massachusetts, USA
    Health Aff (Millwood) 25:W262-71. 2006
    ....
  43. ncbi request reprint Cost-effectiveness of PET in the diagnosis of Alzheimer disease
    Pamela M McMahon
    Institute for Technology Assessment, Massachusetts General Hospital, Zero Emerson Place, Suite 2H, Boston, MA 02114, USA
    Radiology 228:515-22. 2003
    ..To evaluate the cost-effectiveness of positron emission tomography (PET) in the diagnosis of Alzheimer disease (AD) in community-dwelling patients with mild or moderate dementia who present to specialized AD centers...
  44. ncbi request reprint A strategic plan for integrating cost-effectiveness analysis into the US healthcare system
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, 800 Washington St, 063, Boston, MA 02111, USA
    Am J Manag Care 14:185-8. 2008
    ..Panelists emphasized the importance of the Medicare program taking a lead role, and the need for new "infrastructure," in the form of either a new institute for conducting research or increased funding for existing institutions...
  45. ncbi request reprint Public attitudes about genetic testing for Alzheimer's disease
    P J Neumann
    Program on the Economic Evaluation of Medical Technology at the Harvard School of Public Health, Boston, Massachusetts, USA
    Health Aff (Millwood) 20:252-64. 2001
    ..The results suggest that people value genetic testingfor personal and financial reasons, but they also underscore the need to counsel potential recipients carefully about the accuracy and implications of test information...
  46. ncbi request reprint Economic evaluation in the US: what is the missing link?
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Care Policy, Tufts New England Medical Center, Boston, Massachusetts, USA
    Pharmacoeconomics 24:1163-8. 2006
    ..However, a more likely outcome is the ongoing indirect use of cost-effectiveness information...
  47. doi request reprint Medicare's national coverage decisions for technologies, 1999-2007
    Peter J Neumann
    Institute for Clinical Research and Health Policy Studies, at Tufts Medical Center in Boston, Massachusetts, USA
    Health Aff (Millwood) 27:1620-31. 2008
    ....
  48. ncbi request reprint When is critical care medicine cost-effective? A systematic review of the cost-effectiveness literature
    Daniel Talmor
    Department of Anesthesia, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
    Crit Care Med 34:2738-47. 2006
    ..Cost-effectiveness analyses (CEAs) have become increasingly common to aid decisions about the allocation of scarce healthcare resources...
  49. doi request reprint Decision analytic models for Alzheimer's disease: state of the art and future directions
    Joshua T Cohen
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, MA, USA
    Alzheimers Dement 4:212-22. 2008
    ....
  50. doi request reprint 30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement
    Peter J Neumann
    The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, Massachusetts, USA
    Pharmacoeconomics 27:861-72. 2009
    ..The results highlight that there are many opportunities for efficient healthcare investment, among pharmaceutical and non-pharmaceutical interventions, just as there are many investments that are inefficient...
  51. ncbi request reprint Valuing children's health: a comparison of cost-utility analyses for adult and paediatric health interventions in the US
    Joseph A Ladapo
    Harvard Medical School and Harvard Graduate School of Arts and Sciences, Boston, Massachusetts, USA
    Pharmacoeconomics 25:817-28. 2007
    ....
  52. doi request reprint Quality-adjusted life years in cancer: pros, cons, and alternatives
    R M Woodward
    Boston Health Economics, Inc, Waltham, MA 02451, USA
    Eur J Cancer Care (Engl) 22:12-9. 2013
    ..In this paper, we summarise the use of the quality-adjusted life years to assess the value of cancer care and suggest potential ways to improve upon value measurement in cancer coverage and reimbursement decisions...
  53. ncbi request reprint FEV(1) is associated with risk of asthma attacks in a pediatric population
    A L Fuhlbrigge
    Channing Laboratory, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115-5805, USA
    J Allergy Clin Immunol 107:61-7. 2001
    ..CONCLUSION: The strong association between FEV(1)% and risk of asthma attack over the subsequent year supports an emphasis on objective measures of lung function in assessment of risk for adverse asthma outcomes...
  54. doi request reprint Migraine frequency and health utilities: findings from a multisite survey
    Jeffrey S Brown
    Department of Ambulatory Care and Prevention, Harvard Medical School Harvard Pilgrim Health Care, Boston, MA, USA
    Value Health 11:315-21. 2008
    ..Assess the relationship between migraine frequency and health utility...
  55. ncbi request reprint Cross-national comparison of technology assessment processes
    Anna García-Altés
    Harvard School of Public Health, Boston, Massachusetts 02115, USA
    Int J Technol Assess Health Care 20:300-10. 2004
    ..To compare methods and results among four health technology assessment organizations in different countries...
  56. ncbi request reprint Does preventive care save money? Health economics and the presidential candidates
    Joshua T Cohen
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, Boston, USA
    N Engl J Med 358:661-3. 2008
  57. pmc When is cancer care cost-effective? A systematic overview of cost-utility analyses in oncology
    Dan Greenberg
    Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA 02111, USA
    J Natl Cancer Inst 102:82-8. 2010
    ..Because we found only modest improvement in the quality of studies, we suggest that journals provide specific guidance for reporting CUA and assure that authors adhere to guidelines for conducting and reporting economic evaluations...
  58. ncbi request reprint FDA actions against misleading or unsubstantiated economic and quality-of-life promotional claims: an analysis of warning letters and notices of violation
    Kate A Stewart
    Program on the Economic Evaluation of Medical Technology, Center for Risk Analysis, Harvard School of Public Health, 7218 Huntington Avenue, Boston, MA 02115, USA
    Value Health 5:390-7. 2002
    ..The objective of this study was to understand the types of economic and quality-of-life promotional claims the FDA considers false or misleading...
  59. ncbi request reprint Low-value services in value-based insurance design
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Tufts Medical Center, Boston, MA 02111, USA
    Am J Manag Care 16:280-6. 2010
    ..To identify potentially low-value services for inclusion in value-based insurance design (VBID) programs and to discuss challenges involved in incorporating such information...
  60. pmc Twenty years of cost-effectiveness analysis in medical imaging: are we improving?
    Hansel J Otero
    Department of Radiology, Brigham and Women s Hospital, Harvard Medical School, 75 Francis St, Boston, MA 02115, USA
    Radiology 249:917-25. 2008
    ..S. Panel on Cost-effectiveness in Health and Medicine recommendations affected CEA studies in which imaging technologies were evaluated...
  61. ncbi request reprint Willingness to pay for avoiding coronary restenosis and repeat revascularization: results from a contingent valuation study
    Dan Greenberg
    Harvard Clinical Research Institute, Boston, MA, USA
    Health Policy 70:207-16. 2004
    ..The contingent valuation approach may offer particular advantages when evaluating treatments that improve short-term health outcomes...
  62. ncbi request reprint Quality-adjusted life years: how useful in medico economic studies
    Carmen A Brauer
    Program on the Economic Evaluation of Medical Technology, Harvard Center for Risk Analysis, Harvard School of Public Health, Boston, MA, USA
    Fundam Clin Pharmacol 19:603-7. 2005
    ..The purpose of this paper is to highlight some of the issues surrounding the use of QALYs and to encourage researchers to present their methodology in a clear and transparent way...
  63. doi request reprint Key principles for the improved conduct of health technology assessments for resource allocation decisions
    Michael F Drummond
    Centre for Health Economics, University of York, Heslington, York, UK
    Int J Technol Assess Health Care 24:244-58; discussion 362-8. 2008
    ..The principles are organized into four sections: (i) "Structure" of HTA programs; (ii) "Methods" of HTA; (iii) "Processes for Conduct" of HTA; and (iv) "Use of HTAs in Decision Making."..
  64. ncbi request reprint When is evidence sufficient?
    Karl Claxton
    University of York, United Kingdom
    Health Aff (Millwood) 24:93-101. 2005
    ..Value-of-information analysis, a related methodology, helps to determine whether it is worthwhile to collect additional information as well as the type of research that would be most helpful...
  65. pmc Bias in published cost effectiveness studies: systematic review
    Chaim M Bell
    St Michael s Hospital, Toronto, Ontario, Canada M5B 1W8
    BMJ 332:699-703. 2006
    ....
  66. ncbi request reprint Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report
    Louis P Garrison
    University of Washington, Seattle, WA 98195, USA
    Value Health 10:326-35. 2007
    ....
  67. ncbi request reprint Budget impact analyses get some respect
    Peter J Neumann
    Value Health 10:324-5. 2007
  68. ncbi request reprint What affects the quality of economic analysis for life-saving investments?
    Robert W Hahn
    AEI Brookings Joint Center for Regulatory Studies, Washington, DC 20036, USA
    Risk Anal 26:641-55. 2006
    ..Somewhat surprisingly, a study's funding source and whether it is affiliated with industry are not significantly correlated with the quality index. Finally, neither time nor the panel guidelines had an impact on the index...
  69. ncbi request reprint The economic burden of intracerebral hemorrhage: evidence from managed care
    Mason W Russell
    Boston Health Economics, Waltham, Massachusetts 02451, USA
    Manag Care Interface 19:24-8, 34. 2006
    ..Treatment costs for ICH to private payers appear to be considerable and may reflect a sizable long-term financial burden to U.S. health plans...
  70. ncbi request reprint Diffusion of published cost-utility analyses in the field of health policy and practice
    Seema S Sonnad
    Department of Surgery, University of Pennsylvania, Philadelphia, Pennsylvania 19104 4283, USA
    Int J Technol Assess Health Care 21:399-402. 2005
    ..The diffusion of cost-utility analyses (CUAs) through the medical literature was examined, documenting visible patterns and determining how they correspond with expectations about the diffusion of process innovations...
  71. ncbi request reprint Challenges ahead for federal technology assessment
    Peter J Neumann
    Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies, Tufts New England Medical Center, MA, USA
    Health Aff (Millwood) 26:w150-2. 2007
    ..Efforts are also needed to prioritize research, to communicate it to decision-makers, to involve stakeholders in the process, and to include cost-effectiveness information...
  72. ncbi request reprint Biotechnology and Medicare's new technology policy: lessons from three case studies
    Patricia Seliger Keenan
    Division of Health Policy and Administration, Department of Epidemiology and Public Health, Yale University School of Medicine in New Haven, Connecticut, USA
    Health Aff (Millwood) 25:1260-9. 2006
    ..The cases suggest Medicare's ongoing challenge to balance access considerations, the role and strength of evidence, and cost consequences of new treatments...
  73. ncbi request reprint A synthesis of cost-utility analysis literature in infectious disease
    Patricia W Stone
    Columbia University School of Nursing, New York, NY 10032, USA
    Lancet Infect Dis 5:383-91. 2005
    ..The results of cost-utility analyses have important implications for the development of clinical guidelines and resource allocation decisions. More trained investigators and better peer-review processes are needed...
  74. ncbi request reprint Trends in cost effectiveness analyses in orthopaedic surgery
    Carmen A Brauer
    Department of Orthopaedic Surgery, British Columbia Children s Hospital, Vancouver, BC, Canada
    Clin Orthop Relat Res 457:42-8. 2007
    ....
  75. ncbi request reprint The impact of Medicare modernization on coverage policy: recommendations for reform
    Susan Bartlett Foote
    Division of Health Services Research and Policy, School of Public Health, University of Minnesota, Minneapolis, Minn 55455, USA
    Am J Manag Care 11:140-2. 2005
  76. ncbi request reprint Prevalence and impact of medical comorbidity in Alzheimer's disease
    P Murali Doraiswamy
    Department of Psychiatry, Duke University Medical Center, Durham, North Carolina 27710, USA
    J Gerontol A Biol Sci Med Sci 57:M173-7. 2002
    ..We examined the prevalence of comorbid medical illnesses in Alzheimer's disease (AD) patients at different severity levels. We also examined the effect of cumulative medical comorbidity on cognition and function...
  77. ncbi request reprint Economic burden of pertussis and the impact of immunization
    J Jaime Caro
    Caro Research Institute, Concord, MA 01742, USA
    Pediatr Infect Dis J 24:S48-54. 2005
    ..Despite the existing gaps in data, further research using the most current data should facilitate decisions on new vaccination strategies by describing conditions for favorable results and quantifying the margin of uncertainty...
  78. ncbi request reprint Quality of abstracts of papers reporting original cost-effectiveness analyses
    Allison B Rosen
    Division of General Medicine, University of Michigan Health Systems, Department of Health Management and Policy, University of Michigan School of Public Health, Ann Arbor Veterans Affairs Medical Center, Ann Arbor, MI 48109, USA
    Med Decis Making 25:424-8. 2005
    ..The authors examined the extent to which abstracts of published CEAs include key data elements (intervention, comparator, target population, study perspective) and assessed the effect of journal characteristics on reporting quality...
  79. ncbi request reprint Development and validation of a grading system for the quality of cost-effectiveness studies
    Chiun Fang Chiou
    Zynx Health Inc, Cerner Corporation, Beverly Hills, California 90212, USA
    Med Care 41:32-44. 2003
    ..To provide a practical quantitative tool for appraising the quality of cost-effectiveness (CE) studies...
  80. ncbi request reprint Examining the value and quality of health economic analyses: implications of utilizing the QHES
    Joshua J Ofman
    Zynx Health Inc, 9100 Wilshire Blvd, East Tower, Suite 655, Beverly Hills, CA 90212, USA
    J Manag Care Pharm 9:53-61. 2003
    ..To examine the increasing use of health economic studies and practical implications of evaluating their quality utilizing the Quality of Health Economic Studies (QHES) instrument...
  81. ncbi request reprint Cost-effectiveness of topiramate in migraine prevention: results from a pharmacoeconomic model of topiramate treatment
    Jeffrey S Brown
    Boston Health Economics, Inc, Waltham, MA 02451, USA
    Headache 45:1012-22. 2005
    ..This cost-effectiveness model assesses the clinical and economic impact of topiramate (TPM) therapy versus no preventive treatment for migraine headache in the United States...
  82. ncbi request reprint How often do sensitivity analyses for economic parameters change cost-utility analysis conclusions?
    Bruce R Schackman
    Division of Outcomes and Effectiveness Research, Department of Public Health, Weill Medical College of Cornell University, New York 10021, USA
    Pharmacoeconomics 22:293-300. 2004
    ..Sensitivity analyses for health-related QOL (HR-QOL), cost and discount rate economic parameters are of particular interest because they measure the effects of methodological and estimation uncertainties...

Research Grants3

  1. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2001
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
  2. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2002
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..
  3. A Comprehensive Database of Cost-Effectiveness Analyses
    Peter Neumann; Fiscal Year: 2003
    ..The web-based data should also understand the needs of different scientists to be understood and policymakers, and bridges to be built across disparate communities. ..